RecruitingPhase 4

Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC

Egypt100 participantsStarted 2023-08-15

Plain-language summary

We will give an anticoagulant against portal vein thrombosis, and watch for the results.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Portal vein thrombosis, Cirrhosis, With or without HCC, Child A \& B Exclusion Criteria: * Platelets\<10000, Createnine \>1.9, Budd ciarri, Uncontrolled active bleeding

What they're measuring

Portal vein thrombosis

Timeframe: 6 months

Trial details

NCT IDNCT07132515

SponsorMansoura University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-08

Contact for this trial

Dalia Elsayed Ganady, MBBS

+201095529264 dalia.tawfik97@gmail.com

View on ClinicalTrials.gov More Cirrhosis trials